MedTrace Logo

Nigella 5 in the Treatment of SARS COV2 (COVID-19)

NCT04914767 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 500

Last updated 2022-02-21

No results posted yet for this study

Summary

The world is currently facing a crisis because of this potentially fatal situation of the COVID-19 epidemic without proven efficacy for any drug treatment, while the vaccination is not yet.

This epidemic is caused by a new betacorona virus, now called SARS-CoV-2. The most common symptoms reported are fever, cough or chest tightness, and dyspnea. Most cases have a mild course

Conditions

  • SARS-CoV2 Infection

Interventions

DRUG

Nigella

The patient will receive a study treatment containing 100 capsules: * One capsule every two hours for the first three days. * From the fourth day, the patient will take one capsule, three times a day for 12 days.

DRUG

Placebo

The patient will receive a study treatment containing 100 capsules: * One capsule every two hours for the first three days. * From the fourth day, the patient will take one capsule, three times a day for 12 days.

Sponsors & Collaborators

  • Hôpital Universitaire Sahloul

    lead OTHER

Principal Investigators

  • Riadh Boukef, professor · CHU Sahloul, Sousse, Tunisia

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
40 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-03-01
Primary Completion
2021-10-30
Completion
2021-12-31

Countries

  • Tunisia

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04914767 on ClinicalTrials.gov